345 related articles for article (PubMed ID: 21994366)
1. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.
Wang X; Sirianni A; Pei Z; Cormier K; Smith K; Jiang J; Zhou S; Wang H; Zhao R; Yano H; Kim JE; Li W; Kristal BS; Ferrante RJ; Friedlander RM
J Neurosci; 2011 Oct; 31(41):14496-507. PubMed ID: 21994366
[TBL] [Abstract][Full Text] [Related]
2. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
4. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
[TBL] [Abstract][Full Text] [Related]
5. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
[TBL] [Abstract][Full Text] [Related]
7. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.
Zhang Y; Cook A; Kim J; Baranov SV; Jiang J; Smith K; Cormier K; Bennett E; Browser RP; Day AL; Carlisle DL; Ferrante RJ; Wang X; Friedlander RM
Neurobiol Dis; 2013 Jul; 55():26-35. PubMed ID: 23537713
[TBL] [Abstract][Full Text] [Related]
8. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal 'clock' gene expression in striatal neurons in vitro.
Imbesi M; Arslan AD; Yildiz S; Sharma R; Gavin D; Tun N; Manev H; Uz T
J Pineal Res; 2009 Jan; 46(1):87-94. PubMed ID: 18798788
[TBL] [Abstract][Full Text] [Related]
9. Gene structures, biochemical characterization and distribution of rat melatonin receptors.
Ishii H; Tanaka N; Kobayashi M; Kato M; Sakuma Y
J Physiol Sci; 2009 Jan; 59(1):37-47. PubMed ID: 19340560
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
Jiang M; Wang J; Fu J; Du L; Jeong H; West T; Xiang L; Peng Q; Hou Z; Cai H; Seredenina T; Arbez N; Zhu S; Sommers K; Qian J; Zhang J; Mori S; Yang XW; Tamashiro KL; Aja S; Moran TH; Luthi-Carter R; Martin B; Maudsley S; Mattson MP; Cichewicz RH; Ross CA; Holtzman DM; Krainc D; Duan W
Nat Med; 2011 Dec; 18(1):153-8. PubMed ID: 22179319
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanisms.
Das A; Wallace G; Reiter RJ; Varma AK; Ray SK; Banik NL
J Pineal Res; 2013 Jan; 54(1):58-68. PubMed ID: 22823500
[TBL] [Abstract][Full Text] [Related]
12. Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin.
Pitts A; Dailey K; Newington JT; Chien A; Arseneault R; Cann T; Thompson LM; Cumming RC
J Biol Chem; 2012 Jun; 287(27):22717-29. PubMed ID: 22577145
[TBL] [Abstract][Full Text] [Related]
13. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
[TBL] [Abstract][Full Text] [Related]
14. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
15. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
16. Spatial and temporal requirements for huntingtin (Htt) in neuronal migration and survival during brain development.
Tong Y; Ha TJ; Liu L; Nishimoto A; Reiner A; Goldowitz D
J Neurosci; 2011 Oct; 31(41):14794-9. PubMed ID: 21994396
[TBL] [Abstract][Full Text] [Related]
17. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
18. Melatonin partially protects 661W cells from H
Sánchez-Bretaño A; Baba K; Janjua U; Piano I; Gargini C; Tosini G
Mol Vis; 2017; 23():844-852. PubMed ID: 29259391
[TBL] [Abstract][Full Text] [Related]
19. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
